Tibulizumab (ZB-106)
Systemic Sclerosis
Key Facts
About Zura Bio
Zura Bio is focused on creating transformative treatments for complex autoimmune diseases through a dual antagonism strategy, targeting multiple inflammatory pathways simultaneously to improve efficacy. Founded in 2022, the company has rapidly built a portfolio of three clinical-stage assets in-licensed from Pfizer and Eli Lilly, with its lead program in Phase 2 development. Zura Bio went public via a SPAC merger in 2023 and has since raised significant capital to advance its pipeline, positioning itself to address high unmet needs in conditions like systemic sclerosis.
View full company profileAbout Zura Bio
Zura Bio is focused on creating transformative treatments for complex autoimmune diseases through a dual antagonism strategy, targeting multiple inflammatory pathways simultaneously to improve efficacy. Founded in 2022, the company has rapidly built a portfolio of three clinical-stage assets in-licensed from Pfizer and Eli Lilly, with its lead program in Phase 2 development. Zura Bio went public via a SPAC merger in 2023 and has since raised significant capital to advance its pipeline, positioning itself to address high unmet needs in conditions like systemic sclerosis.
View full company profileAbout Zura Bio
Zura Bio is focused on creating transformative treatments for complex autoimmune diseases through a dual antagonism strategy, targeting multiple inflammatory pathways simultaneously to improve efficacy. Founded in 2022, the company has rapidly built a portfolio of three clinical-stage assets in-licensed from Pfizer and Eli Lilly, with its lead program in Phase 2 development. Zura Bio went public via a SPAC merger in 2023 and has since raised significant capital to advance its pipeline, positioning itself to address high unmet needs in conditions like systemic sclerosis.
View full company profileAbout Zura Bio
Zura Bio is focused on creating transformative treatments for complex autoimmune diseases through a dual antagonism strategy, targeting multiple inflammatory pathways simultaneously to improve efficacy. Founded in 2022, the company has rapidly built a portfolio of three clinical-stage assets in-licensed from Pfizer and Eli Lilly, with its lead program in Phase 2 development. Zura Bio went public via a SPAC merger in 2023 and has since raised significant capital to advance its pipeline, positioning itself to address high unmet needs in conditions like systemic sclerosis.
View full company profileTherapeutic Areas
Other Systemic Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| KYV-101 | Kyverna Therapeutics | Phase 1/2 |
| rese-cel (resecabtagene autoleucel) | Cabaletta Bio | Phase 1/2 |